The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease

Acta Neurologica Scandinavica

Volumn 124, Issue 3, 2011, Pages 196-201

  Lee, M S ^a   Lyoo, C H ^a   Ryu, Y H ^a   Lim, H S ^a   Nam, C M ^a   Kim, H S ^b   Rinne, J O ^c  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

18F fluorodeoxy glucose positron emission tomography (FDG PET); Aging; Parkinson's disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE; AGED; ARTICLE; BRADYKINESIA; CINGULATE GYRUS; CONTROLLED STUDY; GLUCOSE BRAIN LEVEL; GLUCOSE TRANSPORT; HUMAN; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; RIGIDITY; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AGED, 80 AND OVER; AGING; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 79953029131     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01446.x     Document Type: Article

References (29)

1. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1987;45:1-18.
2. De Jong JD, Burns BD. Parkinson's disease - a random process. Can Med Assoc J 1967;97:49-56.
3. Levy G, Louis ED, Cote L et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62:467-72.
4. Borghammer P, Chakravarty M, Jonsdottir KY et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 2010;214:303-17.
5. Quarantelli M, Berkouk K, Prinster A et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004;45:192-201.
6. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
7. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-7.
8. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
9. Kumakura Y, Vernaleken I, Buchholz HG et al. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol Aging 2010;31:447-63.
10. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
11. Kubis N, Faucheux BA, Ransmayr G et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000;123:366-73.
12. Hallett M. Parkinson revisited: pathophysiology of motor signs. Adv Neurol 2003;91:19-28.
13. Marie RM, Barre L, Rioux P, Allain P, Lechevalier B, Baron JC. PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm 1995;9:55-71.
14. Eidelberg D, Moeller JR, Dhawan V et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
15. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 1991;30:365-74.
16. Newman RP, Lewitt PA, Jaffe M, Calne DB, Larsen TA. Motor function in the normal aging population: treatment with levodopa. Neurology 1985;35:571-3.
17. Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 2002;16:1-14.
18. Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 1991;14:21-7.
19. Mortimer JA. Human motor behavior and aging. Ann N Y Acad Sci 1988;515:54-66.
20. Diamond SG, Markham CH, Hoehn MM, Mcdowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989;39:1187-90.
21. Petit-Tabou MC, Landeau B, Desson JF, Desgranges B, Baron JC. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 1998;7:176-84.
22. Yanase D, Matsunari I, Yajima K et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005;32:794-805.
23. Peppard RF, Martin WR, Carr GD et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-8.
24. Terry RD, Deteresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol 1987;21:530-9.
25. Peters A, Morrison JH, Rosene DL, Hyman BT. Feature article: are neurons lost from the primate cerebral cortex during normal aging? Cereb Cortex 1998;8:295-300.
26. Peinado MA, Martinez M, Pedrosa JA, Quesada A, Peinado JM. Quantitative morphological changes in neurons and glia in the frontal lobe of the aging rat. Anat Rec 1993;237:104-8.
27. Peters A, Leahu D, Moss MB, Mcnally KJ. The effects of aging on area 46 of the frontal cortex of the rhesus monkey. Cereb Cortex 1994;4:621-35.
28. Goldman-Rakic PS, Brown RM. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981;6:177-87.
29. Rossor MN, Iversen LL, Johnson AJ, Mountjoy CQ, Roth M. Cholinergic deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet 1981;2:1422.